| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 01/30/2003 | WO2003007876A2 N-fatty acid-amino acid conjugates and therapeutic uses |
| 01/30/2003 | WO2003007870A2 Oxazolidinone derivatives as antimicrobials |
| 01/30/2003 | WO2003007869A2 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres |
| 01/30/2003 | WO2003007794A2 Invasion complex and methods of targeting |
| 01/30/2003 | WO2003007686A2 Use of copper chelators to inhibit the inactivation of protein c |
| 01/30/2003 | WO2003002580A8 6-`2-(phosphonomethoxy)alkoxy pyrimidine derivatives having antiviral activity |
| 01/30/2003 | WO2003002522A8 Peptide deformylase inhibitors |
| 01/30/2003 | WO2002089817A3 Anti-virus agent |
| 01/30/2003 | WO2002087554A3 Ef-tu binding agent as antibacterial agent |
| 01/30/2003 | WO2002080939A8 Ionene polymers and their use as antimicrobial agents |
| 01/30/2003 | WO2002062333A9 Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein |
| 01/30/2003 | WO2002057271A3 Thienopyrimidine-based inhibitors of the src family |
| 01/30/2003 | WO2002055056A3 Local use of essential oils for treating herpes labialis |
| 01/30/2003 | WO2002051435A3 New therapeutic uses of smr1 peptides |
| 01/30/2003 | WO2002043786A3 Uses for medical devices having a lubricious, nitric oxide-releasing coating for the therapy of vascular disorders |
| 01/30/2003 | WO2002029035A3 Method to alter sugar moieties |
| 01/30/2003 | WO2002014536A3 Odulating multiple lineage kinase proteins |
| 01/30/2003 | WO2002010393A3 Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |
| 01/30/2003 | WO2002002634A3 Human extracellular matrix and cell adhesion polypeptides |
| 01/30/2003 | WO2001090359A3 G-protein coupled receptors |
| 01/30/2003 | US20030023104 For prolonging or altering the activity of a compound which is a member of the chlorambucil family |
| 01/30/2003 | US20030023092 Reacting tetrahydrofuran compound with oxophilic electrophilic reagent to produce oxazoline compound |
| 01/30/2003 | US20030023084 For use in the oral hygiene |
| 01/30/2003 | US20030023079 For therapy of thrombosis in a mammal |
| 01/30/2003 | US20030023070 For diagnosis, prophylaxis and therapy; therapy of cancer |
| 01/30/2003 | US20030023047 For prevention of influenza virus binding to cells, therapy of schizophrenia and diagnosing chronic viral disease associated with development of cancer |
| 01/30/2003 | US20030023034 p27 (Kip1) -FKBP-12 protein complexes |
| 01/30/2003 | US20030023031 Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents |
| 01/30/2003 | US20030022938 N-fatty acid-amino acid conjugates and therapeutic uses |
| 01/30/2003 | US20030022932 Identifying a bacterium that does not produce autoinducer-2; and contacting the bacterium with an amount of an autoinducer-2 effector that is sufficient to regulate the bacterium |
| 01/30/2003 | US20030022914 Nitric oxide synthase inhibitors |
| 01/30/2003 | US20030022909 Use of methylnaltrexone to treat immune suppression |
| 01/30/2003 | US20030022907 Anxiolytic agents and analgesics |
| 01/30/2003 | US20030022895 2-Amino-benzoxazinones for the treatment of viral infections |
| 01/30/2003 | US20030022893 Hydroxamic and carboxylic acid derivatives |
| 01/30/2003 | US20030022890 Heterocyclic dihydropyrimidine compounds |
| 01/30/2003 | US20030022885 Pyrazole compounds useful as protein kinase inhibitors |
| 01/30/2003 | US20030022883 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 01/30/2003 | US20030022882 Forming the 2-amino-2,4,4-trimethylpentane salt of clavulanic acid and converting that salt into a pharmaceutically acceptable salt of clavulanic acid, such as potassium clavulanate |
| 01/30/2003 | US20030022881 Novel carbapenem derivatives of quarternary salt type |
| 01/30/2003 | US20030022865 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 01/30/2003 | US20030022863 Antiadhesive carbohydrates |
| 01/30/2003 | US20030022853 Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes |
| 01/30/2003 | US20030022852 Biodegradable immunomodulatory formulations and methods for use thereof |
| 01/30/2003 | US20030022849 Nucleic acid vaccines for prevention of flavivirus infection |
| 01/30/2003 | US20030022848 Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression |
| 01/30/2003 | US20030022829 Novel antiviral activities primate theta defensins and mammalian cathelicidins |
| 01/30/2003 | US20030022822 Novel compounds |
| 01/30/2003 | US20030022821 A modified lactoferrin peptide which is cytotoxic, 7 to 25 amino acids in length, with three or more cationic residues and has one or more extra bulky and lipophilic amino acids as compared to the native lactoferrin seuquence |
| 01/30/2003 | US20030022813 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022812 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022354 Protein c derivatives |
| 01/30/2003 | US20030022349 Virulence-associated nucleic acid sequences and uses thereof |
| 01/30/2003 | US20030022321 Novel compounds |
| 01/30/2003 | US20030022226 Prophylactic and therapeutic monoclonal antibodies |
| 01/30/2003 | US20030022181 Streptococcus pneumoniae antigens |
| 01/30/2003 | US20030022178 Identification of sortase gene |
| 01/30/2003 | US20030022172 Polyamide nucleic acid derivatives and agents and processes for preparing them |
| 01/30/2003 | US20030022158 Peptide for use in the treatment of viral infection |
| 01/30/2003 | US20030022149 Enhanced production of safe plasma preparations |
| 01/30/2003 | US20030021857 Plant extracts; viricides, blood flow, alopecia |
| 01/30/2003 | US20030021854 Nanocrystal microbiocide metal |
| 01/30/2003 | US20030021840 High dose solid unit oral pharmaceutical dosage form of amorphous nelfinavir mesylate and process for making same |
| 01/30/2003 | US20030021812 Genetic engineering; vaccines; induction immunology response, antibodies |
| 01/30/2003 | US20030021811 Modulating production of pneumococcal capsular polysaccharide |
| 01/30/2003 | US20030021808 Cd40 ligand adjuvant for respiratory syncytial virus |
| 01/30/2003 | US20030021807 Prevent lentivirus infections; polypeptides |
| 01/30/2003 | US20030021806 Papilloma virus capsomere vaccine formulations and method of use |
| 01/30/2003 | US20030021795 Administering antibody; determination binding to peptide |
| 01/30/2003 | US20030021792 Quantitative analysis; immunosuppressants, anticoagulants |
| 01/30/2003 | US20030021769 Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer |
| 01/30/2003 | US20030021766 Nucleic acid mucosal immunization |
| 01/30/2003 | US20030021765 Polymer conjugates of interferon beta-1a and uses |
| 01/30/2003 | US20030021761 Ionene polymers and their use in treating mucositis |
| 01/30/2003 | US20030021755 Headache therapy |
| 01/30/2003 | US20030021754 Aerosols; vaporization, cooling |
| 01/30/2003 | US20030021753 Delivery of antiemetics through an inhalation route |
| 01/30/2003 | CA2730856A1 Capsular polysaccharide solubilisation and combination vaccines |
| 01/30/2003 | CA2454419A1 Invasion complex and methods of targeting |
| 01/30/2003 | CA2454226A1 Improved heteropolymer complexes and methods for their use |
| 01/30/2003 | CA2454185A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 01/30/2003 | CA2454167A1 Use of a class of antiviral compounds to produce an agent for treating or preventing a virus infection in the respiratory tract |
| 01/30/2003 | CA2454007A1 Tetrahydroquinoxalines acting as bradykinin antagonists |
| 01/30/2003 | CA2453997A1 Porphyrin derivatives for photodynamic therapy |
| 01/30/2003 | CA2453967A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453965A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453959A1 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres |
| 01/30/2003 | CA2453846A1 Substituted isoxazoles and the use thereof as antibiotics |
| 01/30/2003 | CA2453636A1 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 01/30/2003 | CA2453616A1 Pharmaceutical preparations containing ion exchange resins charged with active ingredients |
| 01/30/2003 | CA2453602A1 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | CA2453594A1 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| 01/30/2003 | CA2453294A1 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | CA2453260A1 Vaccine formulation potentiated by the combination of a dna and an antigen |
| 01/30/2003 | CA2452678A1 Combination of eplerenone and an hmg coa reductase inhibitor |
| 01/30/2003 | CA2452653A1 Silencing of gene expression by sirna |
| 01/30/2003 | CA2452421A1 Anti-microbial targeting chimeric pharmaceutical |
| 01/30/2003 | CA2452322A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/30/2003 | CA2451881A1 Novel bisphosphonate derivatives, their preparation methods and uses |
| 01/30/2003 | CA2450437A1 1-phenylsulphonyl-1,3-dihydro-2h-indol-2-one derivatives, their preparation and their therapeutic application |